CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 27 enrolled
Drug / intervention
Lantus (glargine)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00694122
NCT00694122Phase 3Completed
CompareCT.gov

Comparison of Lantus and NPH Insulin in the Dawn Phenomenon

Massachusetts General Hospital·interventional·Posted Jun 10, 2008·Updated Oct 21, 2014

In Brief

A Phase 3 clinical trial evaluating Lantus (glargine) for Type 1 Diabetes and Dawn Phenomenon. Completed, enrolled 27 participants across 1 site.

Detailed Summary

1. To investigate the effect of insulin glargine (Lantus™) vs NPH insulin regarding glycemic control during the early AM (dawn phenomenon) in individuals with type 1 diabetes. 2. To measure hormones implicated in the pathogenesis of the dawn phenomenon in individuals with type 1 diabetes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes, Dawn Phenomenon
CountriesUnited States
CollaboratorsSanofi

Timeline

Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 10, 2008
Enrollment StartJun 1, 2005
Primary CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 18.1 years ago

Interventions

Lantus (glargine)drug

Described in Arm Description